Sharescart Research Club logo

Novateor Research Overview

1. Business Overview

Novateor Research Laboratories Ltd. is an Indian company engaged in the research, development, manufacturing, and marketing of a range of herbal/Ayurvedic healthcare products, cosmetic products, food supplements, and over-the-counter (OTC) products. The company focuses on leveraging traditional Ayurvedic principles and modern research to create products across categories like hair care, skin care, oral care, weight management, and general wellness. Its core business model involves in-house R&D, manufacturing (potentially through own facilities and/or third-party contracts), and direct-to-consumer or retail sales through its branded products. The company generates revenue from the sale of these manufactured and marketed products.

2. Key Segments / Revenue Mix

Novateor's product portfolio broadly categorizes into:

Herbal/Ayurvedic Healthcare Products: Covering various health and wellness needs.

Cosmetic Products: Skincare, haircare, and other beauty-related items.

Food Supplements: Dietary supplements for specific health benefits.

OTC Products: Over-the-counter remedies.

Specific revenue contribution percentages for each segment are not readily available in public domain information for this company. However, the company emphasizes its identity as an "Integrated Ayurvedic and Herbal Healthcare Company," suggesting a strong focus on the healthcare and wellness segments within its product mix.

3. Industry & Positioning

Novateor operates within India's highly competitive Household & Personal Products sector, with a specific focus on the fast-growing Ayurvedic, herbal, and wellness sub-segments. The industry is dominated by large domestic and multinational corporations with extensive distribution networks, brand recognition, and marketing budgets (e.g., HUL, Dabur, Patanjali, Marico, Emami). Novateor positions itself as a specialized player in the Ayurvedic/herbal space, aiming to cater to the increasing consumer demand for natural and traditional health and beauty solutions. Given its size, it is likely a niche player competing against the diversified portfolios of larger companies and numerous smaller regional brands within this segment.

4. Competitive Advantage (Moat)

Novateor's competitive advantages are likely to be developing:

Brand Equity in Ayurvedic/Herbal Space: If they successfully build trust and recognition for their natural formulations, this can be a strong differentiator.

Proprietary Formulations: Expertise in Ayurvedic R&D could lead to unique product compositions that offer perceived efficacy.

Niche Focus: Specialization in herbal/Ayurvedic products allows for targeted marketing and product development, potentially serving specific consumer needs better than generalist companies.

However, scale advantages, extensive distribution networks, or significant switching costs are generally not strong for smaller players in this highly competitive market.

5. Growth Drivers

Increasing Demand for Ayurvedic/Herbal Products: Growing consumer preference for natural, traditional, and chemical-free products in India.

Health and Wellness Trend: Rising awareness and spending on health and wellness products, including supplements and preventive care.

Product Portfolio Expansion: Introduction of new and innovative products under their existing categories or venturing into adjacent ones.

Market Penetration: Expanding distribution channels, both online and offline, to reach a wider customer base across India.

Rising Disposable Incomes: Enabling consumers to spend more on personal care and health-related products.

6. Risks

Intense Competition: Facing stiff competition from well-established domestic and international players with significantly larger resources, brand power, and distribution networks.

Raw Material Price Volatility: Dependence on natural/herbal ingredients, whose supply and prices can be subject to seasonal variations and market fluctuations.

Regulatory Scrutiny: Products in the Ayurvedic, herbal, and supplement categories can be subject to specific regulations regarding claims, labeling, and manufacturing standards.

Consumer Preference Shifts: Evolving consumer trends and preferences could impact demand for certain product categories.

Marketing and Distribution Challenges: Need for substantial investment in branding, advertising, and establishing a robust distribution network to gain market share.

Perception of Efficacy: Maintaining consumer trust in the efficacy of herbal/Ayurvedic formulations is crucial.

7. Management & Ownership

Novateor Research Laboratories Ltd. is promoted by individuals such as Mr. Kanti Bhupendra Shah and Mr. Jayesh Bhupendra Shah, who often play key roles in the company's management and strategic direction. As is common with many smaller listed Indian companies, the promoters typically hold a significant stake in the company, aligning their interests with its long-term performance. Details on specific management experience and corporate governance practices would require a deeper review of their annual reports and public disclosures.

8. Outlook

Novateor operates in a promising segment of the Indian consumer market, driven by the growing consumer inclination towards natural, Ayurvedic, and wellness products. This trend presents a significant opportunity for focused players like Novateor to expand their market share through innovative product development and effective branding. However, the path to growth is fraught with challenges, primarily the formidable competition from larger, more entrenched players who are also increasingly focusing on the herbal/Ayurvedic space. The company's success will depend heavily on its ability to build strong brands, differentiate its products through quality and efficacy, expand its distribution efficiently, and manage marketing expenses effectively to carve out a sustainable niche in this dynamic market.

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Novateor Research Key Financials

Market Cap ₹20 Cr.

Stock P/E 243

P/B 1.8

Current Price ₹32.9

Book Value ₹ 18.3

Face Value 10

52W High ₹54.6

Dividend Yield 0%

52W Low ₹ 20.1

Novateor Research Share Price

| |

Volume
Price

Novateor Research Quarterly Price

Show Value Show %

Novateor Research Peer Comparison

Novateor Research Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Novateor Research Profit & Loss

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 0 0 0 0 0 1 1 1 3
Other Income 0 0 0 0 0 0 0 0 0
Total Income 0 0 1 1 1 1 2 2 3
Total Expenditure 0 0 0 1 1 1 2 2 3
Operating Profit 0 0 0 0 0 -0 0 0 0
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 0 -0 0 0 0
Provision for Tax 0 0 0 0 0 -0 0 0 0
Profit After Tax -0 0 0 -0 0 -0 0 0 0
Adjustments 0 0 0 0 0 0 0 0 0
Profit After Adjustments -0 0 0 -0 0 -0 0 0 0
Adjusted Earnings Per Share 0 0 0.7 -0 0 -0.5 0.1 0.1 0.2

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 200% 44% 0% 0%
Operating Profit CAGR 0% 0% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -43% 11% 34% NA%
ROE Average 1% 1% -0% 1%
ROCE Average 2% 1% 0% 2%

Novateor Research Balance Sheet

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1 1 4 9 9 8 8 9 11
Minority's Interest 0 0 0 0 0 0 0 0 0
Borrowings 1 1 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0
Total Current Liabilities 0 0 0 0 0 0 1 1 2
Total Liabilities 2 2 4 9 9 8 9 10 13
Fixed Assets 2 2 4 3 3 2 2 2 3
Other Non-Current Assets 0 0 0 0 0 0 1 1 0
Total Current Assets 0 0 1 5 5 6 6 8 9
Total Assets 2 2 4 9 9 8 9 10 13

Novateor Research Cash Flow

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 1 1 0 0 0
Cash Flow from Operating Activities 0 0 -0 -3 -0 -1 -1 -1 -1
Cash Flow from Investing Activities -0 0 -2 -0 -0 2 0 -0 -0
Cash Flow from Financing Activities 0 -0 2 4 0 -0 1 1 1
Net Cash Inflow / Outflow -0 0 -0 1 -0 -0 -0 -0 0
Closing Cash & Cash Equivalent 0 0 0 1 1 0 0 0 0

Novateor Research Ratios

# Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0 0.74 -0.02 0.02 -0.47 0.08 0.06 0.17
CEPS(Rs) 0.73 0.78 1.06 0.18 0.22 -0.29 0.25 0.23 0.5
DPS(Rs) 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0 0 11.05 15.65 15.83 15.43 15.57 15.74 15.91
Core EBITDA Margin(%) 42.32 60.18 70.53 -34.88 -175.55 -88.61 -27.62 -27.32 -4.7
EBIT Margin(%) 10.27 11.44 73.2 8.86 9.74 -35 4.44 6.2 6.64
Pre Tax Margin(%) 2.18 2.06 72.39 6.73 8.81 -35.08 3.14 3.84 4.08
PAT Margin (%) -2.18 1.03 53.57 -2 6.29 -30.79 2.91 2.43 2.95
Cash Profit Margin (%) 47.71 79.41 77 22.24 57.49 -19.13 9.71 9.15 8.74
ROA(%) -0.16 0.05 7.1 -0.12 0.13 -2.67 0.43 0.3 0.71
ROE(%) -0.32 0.1 10.41 -0.15 0.16 -3.02 0.49 0.39 1.07
ROCE(%) 0.78 0.57 11.87 0.64 0.23 -3.33 0.7 0.83 1.78
Receivable days 179.97 262.47 94.7 184.41 430.69 155.29 164.45 276.05 210.08
Inventory Days 330.71 575.27 306.41 466.35 935.82 242.81 153.88 190.68 96.52
Payable days 751.97 851.67 1113.89 97.88 60.73 30.39 36.71 137.28 141.82
PER(x) 0 0 0 0 256.56 0 244.06 0 212.12
Price/Book(x) 0 0 0 0.54 0.4 0.55 1.19 0 2.26
Dividend Yield(%) 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 6.7 9.66 7.25 8.88 13.91 5.22 7.59 4.85 6.48
EV/Core EBITDA(x) 11.14 10.76 7.5 26.82 22.82 -22.35 67.47 37.54 52.11
Net Sales Growth(%) 0 -36.34 366.53 -3.2 -52.43 295.15 69.88 -4.23 130.1
EBIT Growth(%) 0 -29.08 2884.81 -88.28 -47.68 -1519.38 121.53 33.76 146.52
PAT Growth(%) 0 130 0 -103.61 249.57 -2035.33 116.05 -20.06 179.18
EPS Growth(%) 0 0 7215.01 -102.21 249.49 -2036.48 116.04 -20.05 179.21
Debt/Equity(x) 0.94 0.88 0 0.02 0.03 0.03 0.11 0.15 0.12
Current Ratio(x) 1.87 2.68 3.52 99.1 49.85 118.43 8.88 6.28 5.6
Quick Ratio(x) 0.86 0.99 1.05 89.94 45.42 108.74 8.11 5.7 5.13
Interest Cover(x) 1.27 1.22 90.44 4.17 10.48 -447.88 3.41 2.62 2.59
Total Debt/Mcap(x) 0 0 0 0.03 0.08 0.06 0.09 0 0.05

Novateor Research Shareholding Pattern

# Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
Promoter 60.87 60.87 60.87 60.87 60.87 60.87 60.87 51.6 50.9 50.75
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 39.13 39.13 39.13 39.13 39.13 39.13 39.13 48.4 49.1 49.25
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Novateor Research News

Novateor Research Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Company has a low return on equity of 1% over the last 3 years.
  • Debtor days have increased from 137.28 to 141.82days.
whatsapp